12,899 results match your criteria vte

Development and validation of a predictive score for venous thromboembolism in newly diagnosed non-small cell lung cancer.

Thromb Res 2021 Oct 21;208:45-51. Epub 2021 Oct 21.

Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China. Electronic address:

Introduction: The risk of venous thromboembolism (VTE) varies among tumour types, and different cancer type-specific risks for VTE prediction remain undefined. We aimed to establish a prediction model for non-small lung cancer (NSCLC)-associated VTE.

Materials And Methods: We analysed data from a prospective cohort of patients with newly diagnosed NSCLC. Read More

View Article and Full-Text PDF
October 2021

Iliofemoral venous stenting in patients with central neuromuscular disorders.

J Vasc Surg Venous Lymphat Disord 2021 Oct 22. Epub 2021 Oct 22.

The RANE Center for Venous and Lymphatic Diseases, Jackson, MS 39216.

Background: Leg swelling in patients with various central neuromuscular disorders is a common clinical scenario and can lead to significant morbidity. The aim of this report is to evaluate a subset of patients with central neuromuscular disorders in whom iliofemoral venous stenting was performed at a specialty venous clinic at a tertiary care hospital.

Methods: From January, 2000 to December, 2020, records of all patients who had a known central neuromuscular disorder and who underwent iliofemoral venous stenting for chronic iliofemoral venous obstruction (CIVO) were retrospectively analyzed. Read More

View Article and Full-Text PDF
October 2021

Respiratory monitoring during neonatal resuscitation using a supraglottic airway device vs. a face mask.

Resuscitation 2021 Oct 22. Epub 2021 Oct 22.

Dept. of Woman's and Child's Health, University of Padova, Padova, Italy.

Objective: To evaluate the respiratory function of asphyxiated infants resuscitated with i-gel supraglottic airway (SGA) vs. face mask (FM) in a low-resource setting.

Methods: In this sub-study from the NeoSupra trial, respiratory function during the first 60 inflations was evaluated in 46 neonates (23 with SGA and 23 with FM) at the Mulago National Referral Hospital, Uganda. Read More

View Article and Full-Text PDF
October 2021

Narrative Review of Antiplatelet and Anticoagulant Medications for Venous Thromboembolism Prevention in Spine Surgery.

Clin Spine Surg 2021 Oct 26. Epub 2021 Oct 26.

Hospital for Special Surgery, New York, NY Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA Weill Cornell Medical College, New York, NY.

Study Design: This was a narrative review.

Objective: The objective of this study was to identify commonly utilized venous thromboembolism (VTE) prophylactic measures, spine surgeon perspective, and provide pharmacologic recommendations from the literature.

Summary Of Background Data: Considered a preventable cause of morbidity and mortality, VTE remains an important iatrogenic diagnosis of concern. Read More

View Article and Full-Text PDF
October 2021

Aspirin Compared With Other Anticoagulants for Use as Venous Thromboembolism Prophylaxis in Elective Orthopaedic Hip and Knee Operations: A Narrative Literature Review.

Cureus 2021 Sep 24;13(9):e18249. Epub 2021 Sep 24.

Surgery, University of Glasgow, Glasgow, GBR.

Although total hip and knee arthroplasty are effective methods for treating arthritis, they have an associated risk of venous thromboembolism (VTE). To reduce this risk, prophylactic agents including aspirin, low-molecular-weight Heparin, vitamin K antagonists, and direct oral anticoagulants are employed for up to 35 days after surgery. This narrative literature review utilised a systematic approach to critically assess the current evidence surrounding the use of aspirin for VTE prophylaxis compared to anticoagulants. Read More

View Article and Full-Text PDF
September 2021

Gamma Delta T-Cell Receptor Lymphoma Causing Bilateral Pulmonary Embolism.

Cureus 2021 Sep 18;13(9):e18072. Epub 2021 Sep 18.

Emergency Medicine, Ascension Genesys Hospital, Grand Blanc, USA.

Pulmonary embolism is a previously uncharacterized complication of primary cutaneous gamma delta T-cell lymphoma (PCGDTL), a type of cutaneous T-cell receptor lymphoma that accounts for less than 1% of non-Hodgkin's lymphomas. We report the first documented case of bilateral pulmonary embolism in the setting of PCGDTL in a 30-year-old woman who presented with acute dyspnea. Read More

View Article and Full-Text PDF
September 2021

Half-Dose Anticoagulation for Venous Thromboembolism and Phlegmasia Cerulea Dolens in a Patient With Recurrent Subdural Hematoma.

Cureus 2021 Sep 17;13(9):e18048. Epub 2021 Sep 17.

Internal Medicine, Guthrie Robert Packer Hospital, Sayre, USA.

Anticoagulation for venous thromboembolism (VTE) in patients with recurrent subdural hematoma (SDH) is challenging. It becomes even more challenging when the patient develops phlegmasia cerulea dolens (PCD). We present a 66-year-old female with a recent history of recurrent SDH who received half-dose heparin therapy for VTE and PCD. Read More

View Article and Full-Text PDF
September 2021

Age, personal and family history are independently associated with venous thromboembolism following acute Achilles tendon rupture.

Injury 2021 Oct 11. Epub 2021 Oct 11.

Department of Trauma, Orthopaedics and Sports Medicine, Mater Dei Hospital, Msida, MSD 2090, Malta; University of Malta Medical School, University of Malta, Msida, MSD 2090, Malta. Electronic address:

Purpose: The primary aim was to determine independent patient, injury and management-related factors associated with symptomatic venous thromboembolism (VTE) following acute Achilles tendon rupture (ATR). The secondary aim was to suggest a clinical VTE risk assessment tool for patients with acute ATR.

Methods: From 2010-2018, 984 consecutive adults (median age 47yrs, 73% [n = 714/984] male) sustaining an acute ATR were retrospectively identified. Read More

View Article and Full-Text PDF
October 2021

Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes.

Thromb Res 2021 Oct 15;208:39-44. Epub 2021 Oct 15.

Univ Rennes, Rennes University Hospital, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Rennes, France; Hematology Laboratory, Rennes University Hospital, Rennes, France. Electronic address:

Background: Direct oral anticoagulants (DOAC) use remains challenging in obese patients treated for Venous-Thrombo-Embolism (VTE) due to the paucity of prospective and dedicated studies.

Objective: To assess rivaroxaban and apixaban concentrations at different time-points after intake, in obese patients followed at a thrombosis center and treated for VTE; to define factors associated with DOAC levels outside the on-therapy ranges; and to evaluate bleeding and thrombosis rates during follow-up.

Methods: Observational prospective study in two French University hospitals. Read More

View Article and Full-Text PDF
October 2021

Venous Thromboembolism for the Practicing Cardiologist.

Cardiol Clin 2021 Nov;39(4):551-566

Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 4th Floor, 375 Longwood Avenue, Boston, MA 02215, USA. Electronic address:

Venous thromboembolism (VTE), encompassing pulmonary embolism (PE) and deep vein thrombosis (DVT), is encountered commonly. Acute PE may present as a high-risk cardiovascular emergency, and acute DVT can cause acute and chronic vascular complications. The goal of this review is to ensure that cardiologists are comfortable managing VTE-including risk stratification, anticoagulation therapy, and familiarity with primary reperfusion therapy. Read More

View Article and Full-Text PDF
November 2021

Arguments for Using Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism.

Healthcare (Basel) 2021 Sep 28;9(10). Epub 2021 Sep 28.

Internal Medicine Department, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.

(1) Background: Patients with cancer with a hypercoagulable state present an increased incidence of venous thromboembolism (VTE). Neoplastic patients with concurrent VTE undergoing anticoagulant treatment face a series of issues. (2) The aim of the present paper is to systematically summarize current VTE management in patients with neoplasia and to review the current clinical evidence from meta-analyses of randomized controlled trials and guidelines regarding the administration of direct oral anticoagulants (DOACs) for cancer-associated VTE. Read More

View Article and Full-Text PDF
September 2021

Direct Oral Anticoagulant Therapy for Isolated Distal Deep Vein Thrombosis Associated with Cancer in Routine Clinical Practice.

J Clin Med 2021 Oct 11;10(20). Epub 2021 Oct 11.

Department of Cardiology, Yokohama City University Medical Center, Yokohama 232-0024, Japan.

Background: The efficacy and bleeding complications of direct oral anticoagulant (DOAC) therapy for isolated distal deep vein thrombosis (IDDVT) associated with cancer in routine clinical practice remain unclear. Moreover, prior studies on prolonged therapy for IDDVT are limited.

Methods: This retrospective study enrolled 1641 consecutive patients with acute venous thromboembolism (VTE) who had received oral anticoagulant therapy, including warfarin or DOAC, between April 2014 and September 2018 in our institutions. Read More

View Article and Full-Text PDF
October 2021

Is There a Predictive Value of High Mean Platelet Volume in Early Diagnosis of Venous Thromboembolism?

Isr Med Assoc J 2021 Oct;23(10):635-638

Department of Hematology Galilee Medical Center, Nahariya, Israel.

Background: Venous thromboembolism (VTE) is a serious disease, which demands a fast accurate diagnosis to begin suitable treatment. It presents a major problem in the emergency department (ED), and its confirmation requires adequate evaluation.

Objectives: To evaluate a potential role of mean platelet volume (MPV) in differentiating VTE from other potential diagnosis in patients with suspected VTE. Read More

View Article and Full-Text PDF
October 2021

Proteinuria and venous thromboembolism in pregnancy: a population-based cohort study.

Clin Kidney J 2021 Sep 11;14(9):2101-2107. Epub 2021 Jan 11.

Department of Medicine, Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.

Background: Pregnancy-associated venous thromboembolism (VTE) is associated with high morbidity and mortality. Identification of risk factors of VTE may lead to improved maternal and foetal outcomes. Proteinuria confers a pro-thrombotic state, however, its association with VTE in pregnancy remains unknown. Read More

View Article and Full-Text PDF
September 2021

Racial and Ethnic Disparities in Cancer Associated Thrombosis.

Thromb Haemost 2021 Oct 20. Epub 2021 Oct 20.

Cardiology, University of Pennsylvania, Philadelphia, United States.

Active malignancy increases the risk of developing venous thromboembolism (VTE) by four- to seven-fold. The risk of VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients with cancer varies based on several clinical factors, such as cancer stage and age. However, race and ethnicity are also associated with increased VTE risk. Read More

View Article and Full-Text PDF
October 2021

Neurological Complications of Pulmonary Embolism: a Literature Review.

Curr Neurol Neurosci Rep 2021 Oct 20;21(10):59. Epub 2021 Oct 20.

Department of Cardiovascular Medicine, Loyola University Medical Center, Maywood, IL, 60153, USA.

Purpose Of Review: The present review discusses in-depth about neurological complications following acute venous thromboembolism (VTE).

Recent Findings: Intracranial hemorrhage, acute ischemic cerebrovascular events, and VTE in brain tumors are described as central nervous system (CNS) complications of PE, while peripheral neuropathy and neuropathic pain are reported as peripheral nervous system (PNS) sequelae of PE. Syncope and seizure are illustrated as atypical neurological presentations of PE. Read More

View Article and Full-Text PDF
October 2021

Efficacy and Safety of Postoperative Intravenous Tranexamic Acid in Total Knee Arthroplasty: A Prospective Randomized Controlled Study.

Orthop Surg 2021 Oct 19. Epub 2021 Oct 19.

Department of Orthopaedics Surgery, Hospital of Anhui Medical University, Hefei, China.

Objective: To assess the efficacy and safety of postoperative intravenous tranexamic acid (TXA) in patients undergoing total knee arthroplasty (TKA).

Methods: From March 2020 to August 2020, all patients undergoing primary unilateral TKA in our hospital were considered in prospective randomized controlled study. Included patients were randomized into three groups to receive either two doses of 15 mg/kg intravenous TXA postoperatively, at 2 and 24 h after closing the incision (group A), or a single dose of 15 mg/kg intravenous TXA 2 h postoperatively (group B), or placebo (group C). Read More

View Article and Full-Text PDF
October 2021

Thromboembolic Events During Treatment with Cisplatin-based Chemotherapy in Metastatic Testicular Germ-cell Cancer 2000-2014: A Population-based Cohort Study.

Eur Urol Open Sci 2021 Oct 15;32:19-27. Epub 2021 Aug 15.

The Cancer Clinic, St. Olavs Hospital, Trondheim, Norway.

Background: Cisplatin-based chemotherapy (CBCT) in testicular cancer (TC) is associated with elevated venous thromboembolism (VTE) risk, but trials evaluating the safety and efficacy of thromboprophylaxis are lacking.

Objective: To evaluate the arterial thromboembolism (ATE) and VTE incidence and risk factors during first-line CBCT for metastatic TC, and the effect of thromboprophylaxis on VTE and bleeding.

Design Setting And Participants: In a population-based study, 506 men administered first-line CBCT during 2000-2014 at three university hospitals in Norway were included. Read More

View Article and Full-Text PDF
October 2021

Fibrinolytic nanocages dissolve clots in the tumor microenvironment, improving the distribution and therapeutic efficacy of anticancer drugs.

Exp Mol Med 2021 Oct 19. Epub 2021 Oct 19.

Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu, 41944, Republic of Korea.

Fibrin, one of the components of the extracellular matrix (ECM), acts as a transport barrier within the core of tumors by constricting the blood vessels and forming clots, leading to poor intratumoral distribution of anticancer drugs. Our group previously developed a microplasmin-based thrombolytic ferritin nanocage that efficiently targets and dissolves clots without causing systemic fibrinolysis or disrupting hemostatic clots. We hypothesized that the thrombolytic nanocage-mediated degradation of fibrin clots in the tumor ECM can lead to enhanced intratumoral drug delivery, especially for nanosized anticancer drugs. Read More

View Article and Full-Text PDF
October 2021

A case-control study on factor V Leiden: an independent, gender-dependent risk factor for venous thromboembolism.

Thromb J 2021 Oct 19;19(1):74. Epub 2021 Oct 19.

Transfusion Research center, High Institute for Research and Education in Transfusion, Tehran, Iran.

Background: Activated protein C resistance (APCR) due to factor V Leiden (FVL) mutation (R506Q) is a major risk factor in patients with venous thromboembolism (VTE). The present study investigated the clinical manifestations and the risk of venous thromboembolism regarding multiple clinical, laboratory, and demographic properties in FVL patients.

Material And Methods: A retrospective cross-sectional analysis was conducted on a total of 288 FVL patients with VTE according to APCR. Read More

View Article and Full-Text PDF
October 2021

Venous Thromboembolism in Hospitalized COVID-19 Patients Treated in a Single Academic Center in Mexico: A Case Series Study.

Vasc Endovascular Surg 2021 Oct 19:15385744211051495. Epub 2021 Oct 19.

27746Tecnologico de Monterrey, Nuevo Leon, Mexico.

Background: The increasing prevalence of venous thromboembolism (VTE) among patients with coronavirus disease 2019 (COVID-19) is a matter of concern as it contributes significantly to patients' morbidity and mortality. Data regarding the optimal anticoagulation regimen for VTE prevention and treatment remain scarce. This study describes the characteristics, treatment, and outcomes of COVID-19 patients with VTE treated in a single academic center in Mexico. Read More

View Article and Full-Text PDF
October 2021

Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw 2021 10 15;19(10):1181-1201. Epub 2021 Oct 15.

National Comprehensive Cancer Network.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer-Associated Venous Thromboembolic Disease focus on the prevention, diagnosis, and treatment of patients with cancer who have developed or who are at risk for developing venous thromboembolism (VTE). VTE is a significant concern among cancer patients, who are at heightened risks for developing as well as dying from the disease. The management of patients with cancer with VTE often requires multidisciplinary efforts at treating institutions. Read More

View Article and Full-Text PDF
October 2021

Comparison of strategies for adherence to venous thromboembolism prophylaxis in high-risk surgical patients: a before and after intervention study.

BMJ Open Qual 2021 Oct;10(4)

Anesthesiology and Perioperative Medicine, Queen's University, Kingston, Ontario, Canada.

Background: Venous thromboembolism (VTE) is a major cause of perioperative morbimortality. Despite significant efforts to advance evidence-based practice, prevention rates remain inadequate in many centres.

Objective: To evaluate the effectiveness of different strategies aimed at improving adherence to adequate VTE prophylaxis in surgical patients at high risk of VTE. Read More

View Article and Full-Text PDF
October 2021

[Pulmonary Embolism].

Pneumologie 2021 Oct 18;75(10):800-818. Epub 2021 Oct 18.

Pulmonary embolism (PE) is a life-threatening disease and the third most frequent cardiovascular cause of death after stroke and myocardial infarction. The annual incidence is increasing (in Germany from 85 cases per 100000 population in the year 2005 to 109 cases per 100000 population in the year 2015). The individual risk for PE-related complications and death increases with the number of comorbidities and severity of right ventricular dysfunction. Read More

View Article and Full-Text PDF
October 2021

Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multi-center cohort study.

Blood Adv 2021 Oct 18. Epub 2021 Oct 18.

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States.

Venous thromboembolism (VTE) with concurrent thrombocytopenia is frequently encountered in patients with cancer. Therapeutic anticoagulation in the setting of thrombocytopenia is associated with a high risk of hemorrhage. Retrospective analyses suggest the utility of modified-dose anticoagulation in this population. Read More

View Article and Full-Text PDF
October 2021

Immune checkpoint inhibitors for cancer and venous thromboembolic events.

Eur J Cancer 2021 Oct 15;158:99-110. Epub 2021 Oct 15.

Cardiovascular Imaging Research Center, Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address:

Background: Immune checkpoint inhibitors (ICIs) are widely used cancer treatments. There are limited data on the risk for developing venous thromboembolism (VTE) among patients on an ICI.

Methods: This was a retrospective study of 2854 patients who received ICIs at a single academic centre. Read More

View Article and Full-Text PDF
October 2021

Thromboembolic and bleeding risks in edoxaban patients with pacemaker and cardiac monitoring procedures: Outcomes of the Global EMIT program.

Pacing Clin Electrophysiol 2021 Oct 18. Epub 2021 Oct 18.

Polyclinic of Bari - Hospital, Department of Cardiology, Bari, Italy.

Introduction: Limited data were published on the management of direct oral anticoagulants in the insertion of pacemaker and cardiac monitoring devices. This study describes the management and outcomes of edoxaban, a direct oral factor Xa inhibitor, in patients undergoing pacemaker or monitoring device implantation in routine clinical practice.

Methods And Results: EMIT-AF/VTE collected data of patients from Europe, Korea, and Taiwan. Read More

View Article and Full-Text PDF
October 2021

Long-Term Survival After Venous Thromboembolism: A Prospective Cohort Study.

Front Cardiovasc Med 2021 1;8:749342. Epub 2021 Oct 1.

University Institute of Clinical Chemistry, Inselspital University Hospital, University of Bern, Bern, Switzerland.

Little is known about long-term survival after the initial treatment of venous thromboembolism (VTE). In a prospective cohort study, we aimed to assess the long-term mortality and key predictor variables relating to disease severity, treatment intensity, and comorbidities. Between 1988 and 2018, 6,243 consecutive patients with VTE from a University outpatient unit were prospectively included and followed until December 2019; clinical characteristics, measures of disease severity, and treatment details were recorded. Read More

View Article and Full-Text PDF
October 2021

Utility of Bronchoscopy With Endobronchial Ultrasound in Diagnosis and Monitoring of Pulmonary Embolism.

Cureus 2021 Sep 14;13(9):e17965. Epub 2021 Sep 14.

Pulmonary/Critical Care Medicine, Salem Pulmonary Associates/Salem Health, Salem, USA.

Pulmonary embolism (PE) is a common diagnosis made in the emergency department (ED). Although CT angiogram remains the preferred diagnostic modality, sometimes it is not possible to obtain due to hemodynamic instability, renal failure, pregnancy, etc. Bronchoscopy with endobronchial ultrasound (EBUS) has been used for the evaluation of mediastinal and hilar lesions. Read More

View Article and Full-Text PDF
September 2021

Increased Incidence of Thrombotic Complications With Non-small Cell Lung Cancer Necessitates Consideration of Prophylactic Anticoagulation in Young Individuals.

Cureus 2021 Sep 6;13(9):e17769. Epub 2021 Sep 6.

Oncology, University of Toledo Medical Center, Toledo, USA.

Venous thromboembolism (VTE) is a common complication in cancer patients and is associated with increased morbidity and mortality. Lung cancer is commonly associated with VTE including pulmonary embolism. We did a retrospective analysis from the 2013 Healthcare Cost and Utilization Project data to determine the role of age as a factor in the development of VTE in this patient group. Read More

View Article and Full-Text PDF
September 2021